ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "osteoporosis"

  • Abstract Number: 1719 • ACR Convergence 2023

    Exploring the Link Between Osteitis and Bone Microstructure Changes in Rheumatoid Arthritis: Role of JAK-STAT Signaling Pathway

    Tsuneyasu Yoshida1, Yoichi Nakayama1, Masao Katsushima2, Yuri Nishida3, Mirei Shirakashi1, Ran Nakashima1, Ryu Watanabe2, Kosaku Murakami4, Hajime Yoshifuji1, Akio Morinobu1 and Motomu Hashimoto2, 1Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 2Department of Clinical Immunology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan, 3Department of Endocrinology and Rheumatology, Kurashiki Central Hospital, Kurashiki, Japan, 4Center for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan

    Background/Purpose: Osteitis on MRI and bone microstructure changes (BMC) on high-resolution peripheral quantitative CT are the earliest signs of arthritis, preceding the development of bone…
  • Abstract Number: 2010 • ACR Convergence 2023

    B-FROST: Chronic OBstructive Pulmonary Disease and Vertebral FRacture of OSTeoporotic Origin: Results of a Real-life Cohort

    Amine Mouamnia, Armentieres Hospital Center, Armentieres, France

    Background/Purpose: Chronic obstructive pulmonary disease (COPD) is a chronic disease of the airways. It is mainly caused by smoking. Active smoking is a risk factor…
  • Abstract Number: 2531 • ACR Convergence 2023

    Proton Pump Inhibitor Use Is Associated with Impaired Bone Mineral Density but Not Bone Microarchitecture in Patients with Inflammatory Rheumatic and Musculoskeletal Diseases Taking Glucocorticoids

    Andriko Palmowski1, Gabriela Schmajuk2, Jinoos Yazdany3, Patti Katz4, Jing Li5, Rachael Stovall5, Emma Kersey5, Sabrina Mai Nielsen6, Robin Christensen7, Henning Bliddal8, Zhivana Boyadzhieva9, Udo Schneider9, Tobias Alexander10, Burkhard Muche11, Sandra Hermann11, Edgar Wiebe11 and Frank Buttgereit11, 1Charité - Universitätsmedizin Berlin, Berlin, Germany, 2UCSF / SFVA, San Francisco, CA, 3University of California, General Department of Medicine, Division of Rheumatology, San Francisco, CA, 4University of California San Francisco, San Rafael, CA, 5University of California San Francisco, San Francisco, CA, 6The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark, 7Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen, Denmark, 8The Parker Institute, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark, 9Charité Universitatsmedizine - Berlin, Berlin, Germany, 10Charité Universiätsmedizin Berlin, Dept. Rheumatology, Berlin, Germany, 11Charité Universitätsmedizin, Dept. Rheumatology, Berlin, Germany

    Background/Purpose: Patients with inflammatory rheumatic and musculoskeletal diseases (iRMDs) are at increased risk of osteoporosis and fragility fractures. For this population, whether proton pump inhibitor…
  • Abstract Number: 1818 • ACR Convergence 2023

    Compliance with Romosozumab and Fracture Risk Among Postmenopausal Women in the U.S

    Ye Liu1, Tarun Arora2, Jeffrey Curtis1 and Jingyi Zhang1, 1University of Alabama at Birmingham, Birmingham, AL, 2Foundation for Advancing Science, Technology, Education, and Research, Birmingham, AL

    Background/Purpose: Romosozumab (romo) is a newly approved osteoporosis (OP) medicine for women with postmenopausal OP at high risk of fracture. The utilization pattern of romo…
  • Abstract Number: 2011 • ACR Convergence 2023

    Predicting Fractures in Patients with Isolated Lumbar Spine Osteoporosis Compared to Those with Isolated Hip Osteoporosis

    Nicholas Rossi1, Aamir Saeed2, Aqib Khan3, Hamzah Amin2, Ummaz Nadeem2, Zain Sultan3 and Marwan Bukhari2, 1University Hospitals of Morecambe Bay Foundation Trust, Worksop, United Kingdom, 2Lancaster University, Lancaster, United Kingdom, 3University Hospitals of Morecambe Bay Foundation Trust, Lancaster, United Kingdom

    Background/Purpose: Osteoporosis (OP) presents with fragility fractures, which can cause significant disability and cost to health services globally. There has been extensive research looking at…
  • Abstract Number: 2532 • ACR Convergence 2023

    Prevalence and Disease-Specific Factors Associated with Osteoporosis in Systemic Sclerosis: A Cross-Sectional Analysis of Two Large European Cohorts

    Charles MIDOL1, Edgar Wiebe2, Elise Siegert3, Dörte Huscher4, Helene Behal5, David Launay6, Eric Hachulla7, Eric Matteson8, Vincent Sobanski9 and Frank Buttgereit2, 1Lille University Hospital, Besançon, France, 2Charité Universitätsmedizin, Dept. Rheumatology, Berlin, Germany, 3Department of Rheumatology, Charité University Hospital, Charité Platz 1, D-10117, Berlin, Germany, 4Institute of Biometry and Clinical Epidemiology and Berlin Institute of Health, Charité Universitätsmedizin Berlin, Berlin, Germany, 5Univ. Lille, CHU Lille, Biostatistics Department, Lille, France, 6Univ. Lille, Inserm, CHU Lille, Service de Médecine Interne, Lille, France, 7CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), Lille, France, 8Mayo Clinic College of Medicine and Science, Rochester, MN, USA, Rochester, MN, 9Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, France

    Background/Purpose: Patients with systemic sclerosis (SSc) are at increased risk for osteoporosis (OP) and associated fragility fractures. However, the risks factors and mechanisms driving bone…
  • Abstract Number: 1867 • ACR Convergence 2023

    Peripheral Volumetric Bone Mineral Density and Erosive Disease in Patients with Established Rheumatoid Arthritis: A Cross-Sectional Study Using High-Resolution Peripheral Quantitative Computed Tomography

    Mathias Hänel1, Rasmus Klose-Jensen2, Josephine Therkildsen3, Anne-Birgitte Garm Blavnsfeldt3, Bente Langdahl3, Stinus Gadegaard Hansen4, Kresten Keller5 and Ellen Margrethe Hauge3, 1Rheumatollogy, Aarhus University Hospital, Aarhus, Denmark, 2Rheumatology, Aarhus University Hospital, Aarhus, Denmark, 3Aarhus University Hospital, Aarhus, Denmark, 4Odense University Hospital, Svendborg Sygehus, Svendborg, Denmark, 5Department of Rheumatology, Aarhus University Hospital; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark

    Background/Purpose: High resolution peripheral quantitative computed tomography (HR-pQCT) is a promising imaging modality for assessing volumetric bone mineral density (BMD) in rheumatoid arthritis (RA), and…
  • Abstract Number: 2012 • ACR Convergence 2023

    Incidence of Hyperparathyroidism in Patients with Osteoporosis Treated with Zoledronic Acid or Denosumab

    Carmen Riesco Barcena1, Jose Ivorra Cortes2, Elena Grau Garcia2, Samuel Leal Rodriguez2, Luis Gonzalez Puig2, Anderson Victor Huaylla Quispe2, Pablo Francisco Muñoz Martínez3, Alba Maria Torrat Noves2, Daniel Ramos Castro2, Laura Mas Sanchez4, Ines Canovas Olmos2, Hikmat Charia2, Isabel Martinez Cordellat2, Carmen Najera Herranz2, Rosa Negueroles Albuixech2, Jose Eloy Oller Rodriguez2, Marta De la Rubia Navarro4, Ernesto Tovar Sugrañes2, Elvira Vicens Bernabeu2, Iago Alcantara Alvarez2, Belen Villanueva Mañez2 and Jose Andres Roman Ivorra5, 1Hospital Universitario y Politécnico La Fe, Valencia, Spain, 2Rheumatology Department. HUP La Fe, Valencia, Spain, 3Rheumatology Department. HUP La Fe, Sagunto, Spain, 4Rheumatology Department. HUP La Fe, Valéncia, Spain, 5Hospital Universitari i Politècnic la Fe, Valencia, Spain

    Background/Purpose: Denosumab and Zoledronic acid are antiresorptive drugs commonly used in the treatment of osteoporosis (OP). Zoledronic acid is a third-generation bisphosphonate that inhibits osteoclastic…
  • Abstract Number: 1996 • ACR Convergence 2023

    Variation in Dual-energy X-ray Absorptiometry Reporting: A National Survey of Veterans Health Administration Clinics

    Karla Miller1, Melissa Steffen2, Kimberly McCoy2, Michelle Mengeling2, Heather Davila2, Shylo Wardyn2 and Samantha Solimeo2, 1University of Utah School of Medicine, Salt Lake City, UT, 2Department of Veterans Affairs, Iowa City VA HCS, Iowa City, IA

    Background/Purpose: Dual-energy x-ray absorptiometry (DXA) is an important tool to identify Veterans with osteoporosis, assess fracture risk, and monitor treatment response. Variability in DXA acquisition,…
  • Abstract Number: 2013 • ACR Convergence 2023

    Clinical Characteristics and Risk Factors Associated with Fragility Fractures in Patients with Primary and Idiopathic Mast Cell Activation Syndromes

    Ana Isabel Ramos Lisbona1, Karen Carpio Astudillo1, Filip Skrabski1, Alicia Prieto García1, Isabel Castrejon1, Javier Rivera2, José María Álvaro-Gracia1 and Teresa González1, 1Hospital General Universitario Gregorio Marañón, Madrid, Spain, 2Hospital General Universitario Gregorio Marañon, Madrid, Spain

    Background/Purpose: Mast Cell Activation Syndromes (MCAS) are a group of disorders presenting with episodic multisystem symptoms, predominantly anaphylaxis, as the result of mast cell mediator…
  • Abstract Number: 1998 • ACR Convergence 2023

    How to Tailor Osteoporosis Therapies in Patients with Advanced Liver Disease? Variations of Renal Function by Creatinine and Cystatin C

    Cristina Rodríguez-Alvear1, Mª Carmen López-González2, Elisabet Perea-Martínez3, Antonio Avilés-Hernández3, Eduardo Garín Cascales3, Nuria Buendía Sánchez3, Irene Calabuig-Sais1, Pilar Bernabeu-Gonzálvez3, Agustín Martínez-Sanchís1, Joaquim Esteve-Vives3, PALOMA VELA4, Cayetano Miralles Maciá3, Vega Jovani5 and Mariano Andrés1, 1Dr Balmis Alicante General University Hospital-ISABIAL, Alicante, Spain, 2General University Hospital Dr. Balmis, Alacante, Spain, 3General University Hospital Dr. Balmis, Alicante, Spain, 4Rheumatology, Hospital General Universitario Alicante, Alicante, Spain, 5Department of Rheumatology, Hospital General Universitario Dr. Balmis, Alicante, Spain

    Background/Purpose: Rapid bone loss and increased fractures have been described after liver transplantation. Bisphosphonates are restricted in patients with significant kidney disease, as the drugs…
  • Abstract Number: 2014 • ACR Convergence 2023

    The Role of Orosomucoid 2 in the Regulation of Bone Remodeling by Inhibiting Osteoclastogenesis and Promoting Osteogenesis

    CHONG HYUK CHUNG1, Myeung-Su Lee1 and Chang-hoon Lee2, 1Wonkwang University Hospital, Iksan, South Korea, 2Wonkwang University Hospital, Iksan Jeonbuk, South Korea

    Background/Purpose: Orosomucoid (ORM) is one of the acute phase reactant protein family and is expressed in hepatocytes and secreted into plasma under stress conditions such…
  • Abstract Number: 1999 • ACR Convergence 2023

    One-year Incidence of Clinical Fragility Fractures After Implementing an Osteoporosis Care Protocol in Patients Eligible for Liver Transplantation

    Cristina Rodríguez-Alvear1, Mª Carmen López-González2, Elisabet Perea-Martínez3, Antonio Avilés-Hernández3, Irene Calabuig-Sais1, Maria-Luisa Peral-Garrido4, Pilar Bernabeu-Gonzálvez3, Agustín Martínez-Sanchís1, Joaquim Esteve-Vives3, PALOMA VELA5, Cayetano Miralles Maciá3, Vega Jovani6 and Mariano Andrés1, 1Dr Balmis Alicante General University Hospital-ISABIAL, Alicante, Spain, 2General University Hospital Dr. Balmis, Alacante, Spain, 3General University Hospital Dr. Balmis, Alicante, Spain, 4Vinalopó University Hospital, Novelda, Spain, 5Rheumatology, Hospital General Universitario Alicante, Alicante, Spain, 6Department of Rheumatology, Hospital General Universitario Dr. Balmis, Alicante, Spain

    Background/Purpose: In solid organ transplantation, liver transplants are among those most frequently associated with the development of low bone mass, which occurs in up to…
  • Abstract Number: 2016 • ACR Convergence 2023

    Generation of a Human 3D in Vitro Bone Model That Mimics Glucocorticoid-induced Osteoporosis

    Moritz Pfeiffenberger1, Johannes Plank1, Alexandra Damerau1, Timo Gaber1 and Frank Buttgereit2, 1Charité Universitatsmedizine - Berlin, Berlin, Germany, 2Charité Universitätsmedizin, Dept. Rheumatology, Berlin, Germany

    Background/Purpose: Osteoporosis is a bone disease characterized by low bone mass and changes in bone architecture, leading to pain and reduced mobility in patients. Glucocorticoid-induced…
  • Abstract Number: 2000 • ACR Convergence 2023

    Efficacy of Romosozumab for Glucocorticoid-induced Osteoporosis in Patients with Rheumatic Diseases; A Prospective Study

    Mai Kawazoe1, Kaichi Kaneko2, Shotaro Masuoka3, Soichi yamada3, Zento Yamada3, Sei Muraoka3, Karin Furukawa1, Hiroshi Sato3, Eri Watanabe3, Keiko Koshiba3, Izumi Irita3, Miwa Kanaji3 and Toshihiro Nanki1, 1Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Ota-ku, Japan, 2Division of Rheumatology, Department of Internal Medicine, Toho University Sakura Medical Center, Sakura, Japan, 3Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Tokyo, Japan

    Background/Purpose: Glucocorticoids are widely used to treat a variety of diseases, including rheumatic diseases. Although glucocorticoids improve the outcome for these diseases, various side effects…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 20
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology